Tarlatamab is a bispecific T-cell engager that binds to DLL3 expressed on the surface of tumor cells and CD3 expressed on the surface of T-cells.

Combining immunotherapy with chemotherapy shows promise in enhancing survival rates for extensive-stage small cell lung ...

Panelists discuss how the 5-year CROWN trial data for lorlatinib have shaped the treatment paradigm for ALK+ metastatic ...

The first patient was dosed in the SKYBRIDGE study assessing peluntamig with Tecentriq for advanced small cell lung cancer ...

The Small Cell Lung Cancer market report also offers comprehensive insights into the Small Cell Lung Cancer market size, ...

Afatinib has broad activity against EGFR mutations. However, the approval for uncommon mutations was based on data from 38 ...

An investigational viral immunotherapy extended survival compared with standard care for patients with advanced non-small cell lung cancer who had inadequate response to immune checkpoint inhibitor ...

The investigational oral tyrosine kinase inhibitor (TKI) zongertinib showed promise in patients with previously treated HER2 ...

ImmunityBio's ANKTIVA sBLA for papillary bladder cancer was rejected by the FDA despite prior support, prompting the company ...

Akeso has shared for the first time overall survival data from a high-profile Keytruda head-to-head trial for its PD-1xVEGF ...

The HER2-targeted therapy zongertinib demonstrated clinical benefits for previously treated patients with advanced ...